CONMED Corporation (CNMD) Q4 2024 Earnings Call Transcript
CONMED Corporation (NYSE:CNMD ) Q4 2024 Results Conference Call February 5, 2025 4:30 PM ET Company Participants Pat Beyer - Chief Executive Officer & President Todd Garner - Executive Vice President and Chief Financial Officer Conference Call Participants Rick Wise - Stifel Robbie Marcus - JPMorgan Vik Chopra - Wells Fargo Corporate & Investment Banking Young Li - Jefferies Travis Steed - BofA Securities Operator Thank you for standing by, and welcome to CONMED's Fourth Quarter Fiscal Year 2024 Earnings Conference Call. [Operator Instructions] Before the conference call begins, let me remind you that during this call, management will be making comments and statements regarding its financial outlook, its plans and objectives.
Conmed (CNMD) Surpasses Q4 Earnings and Revenue Estimates
Conmed (CNMD) came out with quarterly earnings of $1.34 per share, beating the Zacks Consensus Estimate of $1.20 per share. This compares to earnings of $1.06 per share a year ago.
Conmed (CNMD) Earnings Expected to Grow: Should You Buy?
Conmed (CNMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Should Value Investors Buy CONMED (CNMD) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
CNMD vs. ALGN: Which Stock Is the Better Value Option?
Investors interested in Medical - Dental Supplies stocks are likely familiar with Conmed (CNMD) and Align Technology (ALGN). But which of these two stocks presents investors with the better value opportunity right now?
Here's Why You Should Retain CONMED Stock in Your Portfolio for Now
CNMD is poised for growth on the back of strong product offerings and recurring revenues but faces headwinds from regulatory challenges, supply-chain constraints and cybersecurity risks.
Here's Why Conmed (CNMD) is a Strong Growth Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Here's Why You Should Retain CONMED Stock in Your Portfolio for Now
CNMD is poised for growth on the back of strong product offerings and recurring revenues but faces headwinds from regulatory challenges, supply-chain constraints and cybersecurity risks.
Here's Why Conmed (CNMD) is a Strong Value Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Why Conmed (CNMD) is a Top Growth Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Conmed (CNMD) is a Top-Ranked Momentum Stock: Should You Buy?
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Why Conmed (CNMD) is a Top Value Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
